A startling twist in treatment as we arrive in London to pursue Amanda's cancer treatment. After Amanda's ovarian cancer came back less than six months after treatment, she was accepted into a Phase 3 clinical trial for a new drug being tested in combination with another drug called Caelyx, aka PLD, aka pegylated liposomal doxorubicin. The new drug, code named EC145, targeted folate-sensitive ovarian cancer tumours. A Phase 3 trial happens after the drug company has already figured out how the drug works, whether it's safe, whether it works, and before it goes to sale. It's the last stage before they roll it out and say "Folks, this is ready for prime time. We've done it." Well, this drug, vintafolide, apparently wasn't ready for prime time. Merck, the company running the PROCEED trial, announced that its regularly scheduled review of data found that "the data suggested that vintafolide was unable to improve progression-free survival (PFS
Video preservation and personal history are the current mission for London, Ontario broadcaster Scott Simpson.